Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer

Select Publications

Baselga J et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A Phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract S3-3.

Bear HD et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Proc ASCO 2011;Abstract LBA1005.


Cancello G et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 2011;127:713-20.


Gianni L et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized Phase II study (‘NeoSphere’). San Antonio Breast Cancer Symposium 2010;Abstract S3-2.


Giuliano AE et al. ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. Proc ASCO 2010;Abstract CRA506.


Gonzalez-Angulo AM et al. SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. Proc ASCO 2011;Abstract TPS104.

Loibl S et al. 313 patients with breast cancer during pregnancy — Results from a prospective and retrospective registry (GBG-20/BIG02-03). San Antonio Breast Cancer Symposium 2010;Abstract S6-2.


Verma S et al. EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen. Proc ASCO 2011;Abstract TPS116.

Von Minckwitz G et al. Neoadjuvant chemotherapy with or without bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44). San Antonio Breast Cancer Symposium 2011;Abstract S4-6.


ALTTO: A randomised, multi-centre, open-label, Phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer. NCT00490139.

A Phase II trial of adjuvant paclitaxel and trastuzumab for node-negative HER2-positive breast cancer. NCT00542451.

BETH: A multicenter Phase III randomized trial of adjuvant therapy for patients with HER2-positive node-positive or high risk node-negative breast cancer comparing chemotherapy plus trastuzumab with chemotherapy plus trastuzumab plus bevacizumab. NCT00625898.

NSABP-B-34: A clinical trial comparing adjuvant clodronate therapy vs placebo in early-stage breast cancer patients receiving systemic chemotherapy and/or hormonal therapy or no therapy. NCT00009945.

SWOG-S0307: Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer. NCT00127205.